CAMBRIDGE, Mass. November 8, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to address obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that management...
CAMBRIDGE, Mass. October 5, 2022 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that John Cronin, M.D., has joined the company as Senior Vice President, Clinical...
CAMBRIDGE, Mass. August 4, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming...
